Impact of COVID-19 pandemic on the etiology and severity of respiratory viral infections in children
- Authors: Sominina A.А.1, Danilenko D.M.1, Komissarov A.B.1, Fadeev A.V.1, Komissarova K.S.1, Pisareva M.M.1, Musayeva T.D.1, Eder V.A.1, Levanyuk T.P.1, Stolyarov K.A.1, Krivitskaya V.Z.1, Petrova E.R.1, Afanasyeva O.I.1, Timonina V.S.2, Obraztsova E.V.1, Golovacheva E.G.1, Dondurey E.A.1,2, Lelenkova E.V.3, Kurskaya O.G.4, Shestopalov A.M.4, Lioznov D.A.1,5
-
Affiliations:
- Smorodintsev Research Institute of Influenza, Ministry of Health
- SPB GUBZ St. Olga Children’s City Hospital
- Federal Scientific Research Institute of Viral Infections “Virom”, Rospotrebnadzor
- Federal Research Center for Fundamental and Translational Medicine, Research Institute of Virology
- First St. Petersburg State Medical University named after Academician I. P. Pavlov
- Issue: Vol 70, No 3 (2025)
- Pages: 254-266
- Section: ORIGINAL RESEARCH
- URL: https://journals.rcsi.science/0507-4088/article/view/310663
- DOI: https://doi.org/10.36233/0507-4088-313
- EDN: https://elibrary.ru/HOFTVE
- ID: 310663
Cite item
Full Text
Abstract
Objective. To analyze the age-related characteristics of the contribution of influenza viruses, RSV, SARS-CoV-2, other pathogens to the development of severe acute respiratory infections (SARI) in children with an assessment of the disease severity depending on its etiology and epidemic period.
Materials and methods. SARI monitoring was carried out over six consecutive epidemic seasons, starting from 2018–2019 in 9 infectious hospitals of three cities of Russia with an assessment of the disease severity depending on its etiology.
Results. Among all hospitalized children, the proportion of children hospitalized with laboratory-confirmed influenza from 2018 to 2020 ranged from 25.7% to 44.7%, and for RSV infection from 25.7% to 26.8%. However, during the peak of the pandemic, these rates dropped significantly to 0.3% and 1.7%, respectively. In the subsequent three seasons (2021–2024), laboratory-confirmed influenza among hospitalized children was registered in 4.5–20.2% of cases, while RSV infection was identified in 13.4–24.1% of cases, accompanied by a shift in viral subgroups. RSV infections were most severe during the 2022–2023 season, presenting in some cases with hyperthermia, hypoxia, dyspnea, and altered consciousness. Among hospitalized children, the proportion with COVID-19 was relatively low in 2020–2021 (0.8–2.4%) but increased significantly to 10.6%–13.6% following the emergence of the Omicron variant in 2022, before decreasing again in subsequent years. The main genetic lineages of SARS-CoV-2 circulating in the Russian Federation are presented.
Conclusion. Influenza and RSV viruses were predominant among viral pathogens identified in hospitalized children aged ≤ 2 years. COVID-19 cases among children were relatively rare and generally less severe compared to RSV and rhinovirus infections.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Anna А. Sominina
Smorodintsev Research Institute of Influenza, Ministry of Health
Author for correspondence.
Email: anna.sominina@influenza.spb.ru
ORCID iD: 0000-0001-9671-0629
Doctor of Medical Sciences, Professor, Head of the Laboratory of the of Risk Factors Assessment in Influenza and ARVI
Russian Federation, 197022, St. PetersburgDarya M. Danilenko
Smorodintsev Research Institute of Influenza, Ministry of Health
Email: daria.baibus@gmail.com
ORCID iD: 0000-0001-6174-0836
Candidate of Biological Sciences, Deputy Director for Scientific Work, Head of the Department of Etiology and Epidemiology
Russian Federation, 197022, St. PetersburgAndrey B. Komissarov
Smorodintsev Research Institute of Influenza, Ministry of Health
Email: a.b.komissarov@gmail.com
ORCID iD: 0000-0003-1733-1255
Head of the lab. of molecular virology
Russian Federation, 197022, St. PetersburgArtem V. Fadeev
Smorodintsev Research Institute of Influenza, Ministry of Health
Email: artem.fadeev@influenza.spb.ru
ORCID iD: 0000-0003-3558-3261
senior researcher, lab. of molecular virology
Russian Federation, 197022, St. PetersburgKsenia S. Komissarova
Smorodintsev Research Institute of Influenza, Ministry of Health
Email: kseniya.sintsova@influenza.spb.ru
ORCID iD: 0000-0002-1465-5548
researcher, lab. of molecular virology
Russian Federation, 197022, St. PetersburgMaria M. Pisareva
Smorodintsev Research Institute of Influenza, Ministry of Health
Email: maria.pisareva@influenza.spb.ru
ORCID iD: 0000-0002-1499-9957
Candidate of Biological Sciences, leading researcher, lab. of molecular virology
Russian Federation, 197022, St. PetersburgTamila D. Musayeva
Smorodintsev Research Institute of Influenza, Ministry of Health
Email: tamila.musaeva@influenza.spb.ru
ORCID iD: 0000-0002-3050-1936
junior researcher, lab. of molecular virology
Russian Federation, 197022, St. PetersburgVeronika A. Eder
Smorodintsev Research Institute of Influenza, Ministry of Health
Email: veronika.eder@influenza.spb.ru
ORCID iD: 0000-0002-9970-3325
PhD, senior researcher, lab. of molecular virology
Russian Federation, 197022, St. PetersburgTatiana P. Levanyuk
Smorodintsev Research Institute of Influenza, Ministry of Health
Email: tatyana.levanyuk@influenza.spb.ru
ORCID iD: 0009-0003-6888-6848
leading programmer, Laboratory of Risk Factors Assessment in Influenza and ARVI
Russian Federation, 197022, St. PetersburgKirill A. Stolyarov
Smorodintsev Research Institute of Influenza, Ministry of Health
Email: kirill@influenza.spb.ru
ORCID iD: 0000-0002-1765-2799
leading programmer, lab. of epidemiology of influenza and ARVI
Russian Federation, 197022, St. PetersburgVera Z. Krivitskaya
Smorodintsev Research Institute of Influenza, Ministry of Health
Email: vera.kriv@influenza.spb.ru
ORCID iD: 0000-0002-9146-0816
Doctor of Biological Sciences, leading researcher, Laboratory of Risk Factors Assessment for Influenza and ARVI
Russian Federation, 197022, St. PetersburgEkaterina R. Petrova
Smorodintsev Research Institute of Influenza, Ministry of Health
Email: ekaterina.petrova@influenza.spb.ru
ORCID iD: 0000-0003-2258-4679
researcher, Laboratory of Risk Factors Assessment for Influenza and ARVI
Russian Federation, 197022, St. PetersburgOlga I. Afanasyeva
Smorodintsev Research Institute of Influenza, Ministry of Health
Email: olga-afanaseva57@mail.ru
ORCID iD: 0000-0002-1229-171X
Doctor of Medical Sciences, Head of the Department of RVI in children
Russian Federation, 197022, St. PetersburgVeronika S. Timonina
SPB GUBZ St. Olga Children’s City Hospital
Email: karina88888888@list.ru
ORCID iD: 0000-0002-2887-0126
Doctor
Russian Federation, 194156, St. PetersburgElena V. Obraztsova
Smorodintsev Research Institute of Influenza, Ministry of Health
Email: alorz@mail.ru
ORCID iD: 0000-0001-8762-6724
Candidate of Medical Sciences, senior researcher of the Department of RVI in children
Russian Federation, 197022, St. PetersburgEkaterina G. Golovacheva
Smorodintsev Research Institute of Influenza, Ministry of Health
Email: ekaterina.golovacheva@influenza.spb.ru
ORCID iD: 0000-0002-1934-7288
Doctor of Medical Sciences, senior researcher of the Department of RVI in children
Russian Federation, 197022, St. PetersburgElena A. Dondurey
Smorodintsev Research Institute of Influenza, Ministry of Health; SPB GUBZ St. Olga Children’s City Hospital
Email: dondureyelena@yandex.ru
ORCID iD: 0000-0003-2382-9172
Candidate of Medical Sciences, senior researcher of the Department of RVI in Children
Russian Federation, 197022, St. Petersburg; 194156, St. PetersburgEvgenya V. Lelenkova
Federal Scientific Research Institute of Viral Infections “Virom”, Rospotrebnadzor
Email: lelenkova_ev@eniivi.ru
ORCID iD: 0000-0003-2004-0977
epidemiologist
Russian Federation, 620030, EkaterinburgOlga G. Kurskaya
Federal Research Center for Fundamental and Translational Medicine, Research Institute of Virology
Email: kurskaya09_@mail.ru
ORCID iD: 0000-0002-1931-2026
Candidate of Medical Sciences, senior researcher, lab. of virology
Russian Federation, 630117, NovosibirskAlexander M. Shestopalov
Federal Research Center for Fundamental and Translational Medicine, Research Institute of Virology
Email: shestopalov2@ngs.ru
ORCID iD: 0000-0002-1880-8708
Doctor of Biological Sciences, Professor, Director
Russian Federation, 630117, NovosibirskDmitry A. Lioznov
Smorodintsev Research Institute of Influenza, Ministry of Health; First St. Petersburg State Medical University named after Academician I. P. Pavlov
Email: dlioznov@yandex.ru
ORCID iD: 0000-0003-3643-7354
Doctor of Medical Sciences, Professor, Director
Russian Federation, 197022, St. Petersburg; 197022, St. PetersburgReferences
- Puig-Barberà J., Tormos A., Trushakova S., Sominina A., Pisareva M., Ciblak M.A., et al. The Global Influenza Hospital Surveillance Network (GIHSN): a new platform to describe the epidemiology of severe influenza. Influenza Other Respir. Viruses. 2015; 9(6): 277–86. https://doi.org/10.1111/irv.12335
- Puig-Barberà J., Mira-Iglesias A., Burtseva E., Cowling B.J., Serhat U., Ruiz-Palacios G.M., et al. Influenza epidemiology and influenza vaccine effectiveness during the 2015-2016 season: results from the Global Influenza Hospital Surveillance Network. BMC Infect. Dis. 2019; 19(1): 415. https://doi.org/10.1186/s12879-019-4017-0
- Baselga-Moreno V., Trushakova S., McNeil S., Sominina A., Nunes M.C., Draganescu A., et al. Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN). BMC Public Health. 2019; 19(1): 487. https://doi.org/10.1186/s12889-019-6713-5
- Puig-Barberà J., Tormos A., Sominina A., Burtseva E., Launay O., Ciblak M.A., et al. First-year results of the Global Influenza Hospital Surveillance Network: 2012-2013 Northern hemisphere influenza season. BMC Public Health. 2014; 14: 564. https://doi.org/10.1186/1471-2458-14-564
- Puig-Barberà J., Burtseva E., Yu H., Cowling B.J., Badur S., Kyncl J., et al. Influenza epidemiology and influenza vaccine effectiveness during the 2014–2015 season: annual report from the Global Influenza Hospital Surveillance Network. BMC Public Health. 2016; 16(Suppl. 1): 757. https://doi.org/10.1186/s12889-016-3378-1
- Simon B., Pichon M., Valette M., Burfin G., Richard M., Lina B., et al. Whole genome sequencing of A(H3N2) influenza viruses reveals variants associated with severity during the 2016–2017 season. Viruses. 2019; 11(2): 108. https://doi.org/10.3390/v11020108
- WHO. Recommended composition of influenza virus vaccines for use in the 2024–2025 northern hemisphere influenza season; 2024. Available at: https://who.int/news/item/23-02-2024-recommendations-announced-for-influenza-vaccine-composition-for-the-2024-2025-northern-hemisphere-influenza-season
- WHO. Global influenza strategy 2019–2030; 2019. Available at: https://who.int/publications/i/item/9789241515320
- Sominina A.A., Danilenko D.M., Komissarov A.B., Pisareva M.M., Musaeva T.D., Stolyarov K.A., et al. Changes in the etiological structure of severe acute respiratory viral infections in children and adults under the influence of the COVID-19 pandemic. Zhurnal mikrobiologii, epidemiologii i immunobiologii. 2024; 101(3): 327–41. https://doi.org/10.36233/0372-9311-532 (in Russian)
- Burtseva E.I., Kolobukhina L.V., Voronina O.L., Ignatjeva A.V., Mukasheva E.A., Panova A.D., et al. Features of the circulation of ARVI pathogens during of emergence and widespread of SARS-CoV-2 in the 2018–2021. Epidemiologiya i vaktsinoprofilaktika. 2022; 21(4): 16–25. https://doi.org/10.31631/2073-3046-2022-21-4-16-26 https://elibrary.ru/rnyfoi (in Russian)
- Burtseva E.I., Kolobukhina L.V., Panova A.D., Mukasheva E.A., Krasnoslobodtsev K.G., Kirillova E.S., et al. Properties of influenza viruses that caused epidemic increases in morbidity in Russia and countries of the world during 2022-2023. The effectiveness of vaccine prophylaxis. Voprosy virusologii. 2024; 69(1): 42–55. https://doi.org/10.36233/0507-4088-211 (in Russian)
- Sominina A.A., Danilenko D.M., Stolyarov K.A., Karpova L.S., Bakaev M.I., Levanyuk T.P., et al. Interference of SARS-CoV-2 with other respiratory viral infections agents during pandemic. Epidemiologiya i vaktsinoprofilaktika. 2021; 20(4): 28–139. https://doi.org/10.31631/2073-3046-2021-20-4-28-39 https://elibrary.ru/cdrnsj (in Russian)
- Olsen S.J., Azziz-Baumgartner E., Budd A.P., Brammer L., Sullivan S., Pineda R.F., et al. Decreased influenza activity during the COVID-19 pandemic – United States, Australia, Chile, and South Africa, 2020. MMWR Morb. Mortal. Wkly Rep. 2020; 69(37): 1305–9. https://doi.org/10.15585/mmwr.mm6937a6
- Adlhoch C., Mook P., Lamb F., Ferland L., Melidou A., Amato-Gauci A.J., et al. Very little influenza in the WHO European Region during the 2020/21 season, weeks 40 2020 to 8 2021. Euro Surveill. 2021; 26(11): 2100221. https://doi.org/10.2807/1560-7917.ES.2021.26.11.2100221
- Meslé M.M.I., Sinnathamby M., Mook P., Pebody R., Lakhani A., Zambon M., et al. Seasonal and inter-seasonal RSV activity in the European Region during the COVID-19 pandemic from autumn 2020 to summer 2022. Influenza Other Respir. Viruses. 2023; 17(11): e13219. https://doi.org/10.1111/irv.13219
- Sominina A., Danilenko D., Komissarov A.B., Pisareva M., Fadeev A., Konovalova N., et al. Assessing the intense influenza A(H1N1)pdm09 epidemic and vaccine effectiveness in the post-COVID season in the Russian Federation. Viruses. 2023; 15(8): 1780. https://doi.org/10.3390/v15081780
- Cohen L.E., Hansen C.L., Andrew M.K., McNeil S.A., Vanhems P., Kyncl J., et al. Predictors of severity of influenza-related hospitalizations: results from the Global Influenza Hospital Surveillance Network (GIHSN). J. Infect. Dis. 2024; 229(4): 999–1009. https://doi.org/10.1093/infdis/jiad303
- Karpova L.S., Volik K.M., Stolyarov K.A., Popovtseva N.M., Stolyarova T.P., Sominina A.A., et al. Features of epidemic process of influenza a(h1n1)pdm09 and a(h3n2) in Russia from 2009 to 2017. Voprosy virusologii. 2018; 63(4): 177–84. https://doi.org/10.18821/0507-4088-2018-63-4-177-184 https://elibrary.ru/ymvmwl (in Russian)
- Popova A.Yu., Smirnov V.S., Egorova S.A., Drozd I.V., Milichkina A.M., Dashkevich A.M., et al. Patterns in the development of collective immunity to SARS-CoV-2 during the COVID-19 pandemic. Meditsinskaya immunologiya. 2023; 25(4): 759–66. https://doi.org/10.15789/1563-0625-PIT-2867 (in Russian)
- Krivitskaya V.Z., Sintsova K.S., Petrova E.R., Sverlova M.V., Sorokin E.V., Tsareva T.R., et al. Genetic and antigenic characteristics of respiratory syncytial virus strains isolated in St. Petersburg in 2013–2016. Voprosy virusologii. 2017; 62(6): 273–82. https://doi.org/10.18821/0507-4088-2017-62-6-273-282 https://elibrary.ru/zuqevd (in Russian)
- Schobel S.A., Stucker K.M., Moore M.L., Anderson L.J., Larkin E.K., Shankar J., et al. Respiratory Syncytial Virus whole-genome sequencing identifies convergent evolution of sequence duplication in the C-terminus of the G gene. Sci. Rep. 2016; 6: 26311. https://doi.org/10.1038/srep26311
- Rosas-Salazar C., Chirkova T., Gebretsadik T., Chappell J.D., Peebles R.S. Jr., Dupont W.D., et al. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study. Lancet. 2023; 401(10389): 1669–80. https://doi.org/10.1016/S0140-6736(23)00811-5
- Gilbert B.E., Patel N., Lu H., Liu Y., Guebre-Xabier M., Piedra P.A., et al. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. Vaccine. 2018; 36(52): 8069–78. https://doi.org/10.1016/j.vaccine.2018.10.073
- Sun M., Lai H., Na F., Li S., Qiu X., Tian J., et al. Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: a systematic review and network meta-analysis. JAMA Netw. Open. 2023; 6(2): e230023. https://doi.org/10.1001/jamanetworkopen.2023.0023
Supplementary files
